	FORM PTO 1449
/C	1 2004 123
	My , E
	Der and

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY DKT NO. SERIAL NO. B185 1210.1 10/659,789

APPLICANT Stenland, et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILING DATE GROUP 09/10/03 1645

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CL.	SUBCL.	FILING DATE IF APPROP.
MH	P1	US 2002/0192794 A1	12/19/02	Dadd, et al.	435	217	
	P2	6,437,102	08/20/02	Lee, et al.	530	412	
	P3	5,290,703	03/01/94	Hsu, et al.	436	71	
	P4	5,141,872	08/25/92	Tamir, I.	436	71	
	P5	5,085,784	02/04/92	Ostreicher, E.A.	210	767	
V	P6	2,390,074	12/04/45	Cohn, E.J.	260	122	

		TOREIGNTATENT DOCUMENTS
		DOCUMENT NO. DATE COUNTRY CL. SUBCL TRANSLATION
	 .	
		OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)
MH	Dl	Alpers, M.P., "Epidemiology and Ecology of Kuru," Vol. 1, pp. 67-90, in Slow
1		Transmissible Diseases of the Nervous System, Academic Press, Inc., publisher, S. B.
		Prusiner and W. J. Hadlow, editors (1979).
	D2	Bolton, D.C., et al., "Isolation and Structural Studies of the Intact Scrapie Agent Protein,"
		Arch. Biochem. Biophys., 258(2): 579-590 (1987).
	D3	Brown, P., et al., "Friendly Fire' in medicine: hormones, homografts, and Creutzfeltd-
		Jakob disease," Lancet, 340(8810): 24-27 (1992).
	D4	Brown, P., et al., "The distribution of infectivity in blood components and plasma
	· ·	derivatives in experimental models of transmissible spongiform encephalopathy,"
	<u> </u>	Transfusion, 38(9): 810-816 (1998).
	D5	Chazot, G., et al., "New Variant of Creutzfeldt-Jakob disease in a 26-year-old French
		man," Lancet, 347(9009): 1181 (1996).
	D6	Lee, D.C., et al., "Monitoring plasma processing steps with a sensitive Western blot assay
		for the detection of the prion protein," J. Virol. Methods, 84: 77-89 (2000).
	D7	Lee, D.C., et al., "A direct relationship between the partitioning of the pathogenic prion
		protein and transmissible spongiform encephalopathy infectivity during the purification of
4		plasma proteins," Transfusion, 41(4): 449-455 (2001).
	D8	Prusiner, S.B., "Molecular Biology of Prion Diseases," Science, 252: 1515-1522 (1991).
	D9	Stenland, C.J., et al., "Partitioning of human and sheep forms of the pathogenic prion
		protein during the purification of therapeutic proteins from human plasma," Transfusion,
		<i>42(11)</i> : 1497-1500 (2002).
$\overline{\mathbf{V}}$	D10	Will, R.G., et al., "A new variant of Creutzfeldt-Jakob Disease in the UK," Lancet,
		347(9006): 921-925 (1996).
XAMINER	71	Michelle Horning/ DATE CONSIDERED 07/27/2006
		1.,21,200

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 2 0 2005 Under the Paperne

PADRIARY

Sheet 1

PTO/SB/08A (08-03) Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

form 1449/PTO

(Use as many sheets as necessary)

Complete ii Known				
Application Number	10/659,789			
Filing Date	09/10/03			
First Named Inventor ·	Stenland, et al.			
Art Unit	1645			
Examiner Name	Unassigned			
Attorney Docket Number	B185 1210.1			

Examiner	Cita	Document Number	U. S. PATENT	Bases Columns Have 14th	
Initials* No.1		Number-Kind Code ^{2 (2 known)}	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MH	P1	US- 5,808,011 A	09/15/98	Gawryl, et al.	
	P2	US- 2004/0171103 A1	09/02/04	Bradley, et al.	
		US-			
		US-			
		US-			
		US-			
		US-		177	
		US-			
		US-			
		US-			
		US-	<u> </u>	-	
		US-			

Exambrer nitlals					Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ
		Country Code ³ "Number ⁴ "Kind Code ⁸ (# known)	MM-DD-YYYY	- Aprilant of Glass accomplish	Or Relevant Figures Appear	۲۰			
	F1	WO 97/45746	12/04/97	McGill Univ.					
علد	F2	WO 01/00235	01/04/01	McGill Univ.		Г			
	F3	WO 02/090379	11/14/02	Serologicals					
						Ĺ			

Examiner /Michelle Horning/ Date 07/27/2006 Slonatura Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Traissuous is autocred.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute fo	Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/659,789	
INFOR				Filing Date	September 10, 2003	
				First Named Inventor	Stenland, et al.	
				Art Unit	1645	
(U	(Use as many sheets as necessary)		essary) ·	Examiner Name	Unassigned	
Sheet 2 of 2		2	Attorney Docket Number	B185 1210.1 (MSC 8015)		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T ²
MH	D1	Pan, K.M., et al., "Purification and Properties of the Cellular Prion Protein from Syrian Hamster Brain," <i>Protein Science</i> , 1: 1343-1352 (1992).	
МН	D2	Van Holten, R.W., et al., "Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter," <i>Transfusion</i> , 52: 999-1004 (2002).	
MH	D3 -	INTERNATIONAL SEARCH REPORT (PTC/US2004/029024, dated 26 November 2004).	

Examiner	/Michelle Horning/	Date	07/27/2006	
Signature		Considered	•	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.